Eligible trials needed to compare SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) with GLP-1 RAs (e.g., semaglutide, liraglutide) or include either class compared to placebo, provided they reported cardiovascular or renal outcomes such as MACE, heart failure hospitalizations, cardiovascular death, or changes in renal function (e.g., eGFR decline). Here, SLC5A2 is linked to heart failure.